PHILADELPHIA -- Dropping aspirin from the antithrombotic regimen after HeartMate 3 left ventricular assist device (LVAD) implantation appeared safer than the usual combination approach in the ...

PHILADELPHIA, PA—Adding to a growing list of medical situations in which aspirin appears to do more harm than good, the ARIES HM3 trial has shown that it can safely be dropped from the antithrombotic ...

Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit Dr. Mehra, who also chaired Abbott's ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The ARIES-HM3 Randomized Clinical Trial assessed the safety and efficacy of excluding aspirin from the antithrombotic regimen in patients with advanced heart failure who have undergone implantation of ...

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has ...

Patients with preexisting indications for aspirin therapy—including those with a history of revascularization, stroke, or peripheral vascular disease—may not need the drug after receiving the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved updated labeling to remove aspirin as part of routine care after implant of Abbott’s fully ...

Dr. Mehra, who also chaired Abbott's ARIES-HM3 study in LVAD patients and is a Professor of Medicine, Harvard University, commented, "In the proposed TECH-LVAD trial, we plan to study a much-needed ...